Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

A federal judge in D.C. recently ruled in favor of the U.S. Health Resources and Services Administration (“HRSA”), an administrative agency under ...

Stocks were boosted in May by easing trade tensions, solid corporate earnings and signs the U.S. economy remains resilient ...

The size of India’s insulin market was an estimated Rs 4,404 crore in April this year, with Indian players making steady ...

Hims & Hers is evolving beyond its original focus, aggressively expanding into peptides and GLP-1. Read why I reiterate my ...

The Pharma world is seeing a big opportunity in GLP-1s – the new innovative fast emerging drugs for diabetes & obesity. Kiran ...

President Trump’s executive order aims to bring down drug prices while optimizing IP protections, and Congress should pass ...

Novo Nordisk and Eli Lilly , the leaders in the highly ... Roche says Trump's drug price order threatens its $50 billion US investment plans U.S. President Donald Trump's executive order on ...

Trump's executive order on drug prices gives no information on actual price targets and it doesn't disclose a plan for how to ...

Get the latest news and real-time alerts from Eli Lilly and Company (LLY) stock at Seeking Alpha. Skip to content Home page Seeking ... Stock Price & Overview Follow $747.12 9.45 (+1.28%) 4:00 PM ...